112 related articles for article (PubMed ID: 17241782)
1. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).
Adorini L; Penna G; Amuchastegui S; Cossetti C; Aquilano F; Mariani R; Fibbi B; Morelli A; Uskokovic M; Colli E; Maggi M
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):689-93. PubMed ID: 17241782
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.
Adorini L; Penna G; Fibbi B; Maggi M
Ann N Y Acad Sci; 2010 Apr; 1193():146-52. PubMed ID: 20398021
[TBL] [Abstract][Full Text] [Related]
4. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
[TBL] [Abstract][Full Text] [Related]
5. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
[TBL] [Abstract][Full Text] [Related]
6. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation.
Comeglio P; Chavalmane AK; Fibbi B; Filippi S; Marchetta M; Marini M; Morelli A; Penna G; Vignozzi L; Vannelli GB; Adorini L; Maggi M
J Endocrinol Invest; 2010 Nov; 33(10):730-8. PubMed ID: 20386089
[TBL] [Abstract][Full Text] [Related]
7. Human bladder as a novel target for vitamin D receptor ligands.
Crescioli C; Morelli A; Adorini L; Ferruzzi P; Luconi M; Vannelli GB; Marini M; Gelmini S; Fibbi B; Donati S; Villari D; Forti G; Colli E; Andersson KE; Maggi M
J Clin Endocrinol Metab; 2005 Feb; 90(2):962-72. PubMed ID: 15572423
[TBL] [Abstract][Full Text] [Related]
8. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
Morelli A; Vignozzi L; Filippi S; Vannelli GB; Ambrosini S; Mancina R; Crescioli C; Donati S; Fibbi B; Colli E; Adorini L; Maggi M
Prostate; 2007 Feb; 67(3):234-47. PubMed ID: 17163492
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L
Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog.
Crescioli C; Ferruzzi P; Caporali A; Mancina R; Comerci A; Muratori M; Scaltriti M; Vannelli GB; Smiroldo S; Mariani R; Villari D; Bettuzzi S; Serio M; Adorini L; Maggi M
Endocrinology; 2003 Jul; 144(7):3046-57. PubMed ID: 12810561
[TBL] [Abstract][Full Text] [Related]
11. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation.
Mariani M; Viganò P; Gentilini D; Camisa B; Caporizzo E; Di Lucia P; Monno A; Candiani M; Somigliana E; Panina-Bordignon P
Hum Reprod; 2012 Jul; 27(7):2010-9. PubMed ID: 22588001
[TBL] [Abstract][Full Text] [Related]
12. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol.
Penna G; Amuchastegui S; Cossetti C; Aquilano F; Mariani R; Sanvito F; Doglioni C; Adorini L
J Immunol; 2006 Dec; 177(12):8504-11. PubMed ID: 17142748
[TBL] [Abstract][Full Text] [Related]
13. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model.
Taniguchi K; Katagiri K; Kashiwagi H; Harada S; Sugimoto Y; Shimizu Y; Arakawa H; Ito T; Yamazaki M; Watanabe T; Kato A; Hoshino E; Takahashi T; Esaki T; Suzuki M; Takeda S; Ichikawa F; Harada A; Sekiguchi N; Ishigai M; Kawata H; Yoneya T; Onuma E; Sudoh M; Aoki Y
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):204-7. PubMed ID: 20304062
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.
Crescioli C; Ferruzzi P; Caporali A; Scaltriti M; Bettuzzi S; Mancina R; Gelmini S; Serio M; Villari D; Vannelli GB; Colli E; Adorini L; Maggi M
Eur J Endocrinol; 2004 Apr; 150(4):591-603. PubMed ID: 15080791
[TBL] [Abstract][Full Text] [Related]
15. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility.
Tiwari A
IDrugs; 2009 Jun; 12(6):381-93. PubMed ID: 19517319
[TBL] [Abstract][Full Text] [Related]
16. Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells.
Sagrinati C; Sottili M; Mazzinghi B; Borgogni E; Adorini L; Serio M; Romagnani P; Crescioli C
Transpl Int; 2010 Sep; 23(9):914-23. PubMed ID: 20302596
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist.
Amuchastegui S; Daniel KC; Adorini L
Transplantation; 2005 Jul; 80(1):81-7. PubMed ID: 16003237
[TBL] [Abstract][Full Text] [Related]
18. Recent role of inflammation in prostate diseases: chemoprevention development opportunity.
Hamid AR; Umbas R; Mochtar CA
Acta Med Indones; 2011 Jan; 43(1):59-65. PubMed ID: 21339547
[TBL] [Abstract][Full Text] [Related]
19. Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells.
Antinozzi C; Corinaldesi C; Giordano C; Pisano A; Cerbelli B; Migliaccio S; Di Luigi L; Stefanantoni K; Vannelli GB; Minisola S; Valesini G; Riccieri V; Lenzi A; Crescioli C
J Steroid Biochem Mol Biol; 2017 Mar; 167():169-181. PubMed ID: 28042053
[TBL] [Abstract][Full Text] [Related]
20. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
